Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19320232 | 0.85 | PLA2G4A (0.35) | PLA2G4AALDH1A1 | |
| SCHEMBL1058273 | 0.78 | PLA2G4A (0.38) | ACLYPLA2G4A | |
| SCHEMBL4206545 | 0.78 | KDM4E (0.44) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL4976795 | 0.76 | PLOD2 (0.38) | PLA2G4AALDH1A1 | |
| SCHEMBL31412009 | 0.76 | KDM4E (0.42) | KDM4EKDM6BKDM5CEGLN1PHF8 | |
| SCHEMBL185832 | 0.76 | — | — | |
| SCHEMBL16465223 | 0.75 | ACLY (0.35) | LDHASRRACLYALDH1A1HMGCR | |
| SCHEMBL5483788 | 0.74 | LDHA (0.44) | LDHASRRACLYALDH1A1HMGCR | |
| SCHEMBL28017992 | 0.74 | EGLN1 (0.41) | LDHASRRACLYKDM4EKDM6B | |
| SCHEMBL8650339 | 0.74 | TDP1 (0.43) | PLA2G4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112899246-B | Aldehyde ketone reductase KmAKR mutant and application thereof in catalytic synthesis of chiral alcohol | 浙江工业大学 | 2022-06-21 | — | — | CN | disclosed |
| EP-3908585-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2021-11-17 | — | — | EP | disclosed |
| WO-2020146194-A1 | IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-07-16 | — | — | WO | disclosed |
| CN-103906735-B | Novel aryl-quinoline derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-07 | — | — | CN | disclosed |
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| US-20060100430-A1 | Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol | LONZA AG (CH) | 2006-05-11 | — | — | US | disclosed |
| EP-1592672-A2 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | Lonza Ltd (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| WO-2004066905-A3 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | LONZA AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004066905-A2 | PROCESS FOR PREPARATION OF 2-ALKOXY-6-(TRIFLUOROMETHYL)PYRIMIDIN-4-OL | LONZA LTD (CH) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-1996012706-A1 | NOVEL ACID PYRAZOLE AND PYRAZOLONE DERIVATIVES FOR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ROUSSEL UCLAF (FR) | 1996-05-02 | — | — | WO | disclosed |
| US-5274111-A | Trifluoromethyl substituted 1H-pyrazoles and derivatives thereof | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-5264451-A | Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | LDHA 3599/4885SRR 3185/4885ACLY 2797/4885 |
| US-20060100430-A1 | Process for preparation of 2-alkoxy-6-(trifluoromethyl)pyrimidin-4-ol | CLCN2, CLIC1, CLIC4 | LDHA 1124/4885SRR 3485/4885ACLY 1527/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | LDHA 4226/4885SRR 4432/4885ACLY 4517/4885 |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | LDHA 2296/4885SRR 1961/4885ACLY 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.